INTERACTION BETWEEN HYALURONIC ACID AND ITS RECEPTORS (CD44, RHAMM) REGULATES THE ACTIVITY OF INFLAMMATION AND CANCER EDITED BY : David Naor PUBLISHED IN : Frontiers in Immunology 1 Frontiers in Immunology July 2016 | Interaction Between Hyaluronic Acid and Its Receptors Frontiers Copyright Statement © Copyright 2007-2016 Frontiers Media SA. All rights reserved. All content included on this site, such as text, graphics, logos, button icons, images, video/audio clips, downloads, data compilations and software, is the property of or is licensed to Frontiers Media SA (“Frontiers”) or its licensees and/or subcontractors. The copyright in the text of individual articles is the property of their respective authors, subject to a license granted to Frontiers. The compilation of articles constituting this e-book, wherever published, as well as the compilation of all other content on this site, is the exclusive property of Frontiers. For the conditions for downloading and copying of e-books from Frontiers’ website, please see the Terms for Website Use. If purchasing Frontiers e-books from other websites or sources, the conditions of the website concerned apply. Images and graphics not forming part of user-contributed materials may not be downloaded or copied without permission. Individual articles may be downloaded and reproduced in accordance with the principles of the CC-BY licence subject to any copyright or other notices. They may not be re-sold as an e-book. As author or other contributor you grant a CC-BY licence to others to reproduce your articles, including any graphics and third-party materials supplied by you, in accordance with the Conditions for Website Use and subject to any copyright notices which you include in connection with your articles and materials. All copyright, and all rights therein, are protected by national and international copyright laws. The above represents a summary only. For the full conditions see the Conditions for Authors and the Conditions for Website Use. ISSN 1664-8714 ISBN 978-2-88919-913-6 DOI 10.3389/978-2-88919-913-6 About Frontiers Frontiers is more than just an open-access publisher of scholarly articles: it is a pioneering approach to the world of academia, radically improving the way scholarly research is managed. The grand vision of Frontiers is a world where all people have an equal opportunity to seek, share and generate knowledge. Frontiers provides immediate and permanent online open access to all its publications, but this alone is not enough to realize our grand goals. Frontiers Journal Series The Frontiers Journal Series is a multi-tier and interdisciplinary set of open-access, online journals, promising a paradigm shift from the current review, selection and dissemination processes in academic publishing. All Frontiers journals are driven by researchers for researchers; therefore, they constitute a service to the scholarly community. At the same time, the Frontiers Journal Series operates on a revolutionary invention, the tiered publishing system, initially addressing specific communities of scholars, and gradually climbing up to broader public understanding, thus serving the interests of the lay society, too. Dedication to quality Each Frontiers article is a landmark of the highest quality, thanks to genuinely collaborative interactions between authors and review editors, who include some of the world’s best academicians. Research must be certified by peers before entering a stream of knowledge that may eventually reach the public - and shape society; therefore, Frontiers only applies the most rigorous and unbiased reviews. Frontiers revolutionizes research publishing by freely delivering the most outstanding research, evaluated with no bias from both the academic and social point of view. By applying the most advanced information technologies, Frontiers is catapulting scholarly publishing into a new generation. What are Frontiers Research Topics? Frontiers Research Topics are very popular trademarks of the Frontiers Journals Series: they are collections of at least ten articles, all centered on a particular subject. With their unique mix of varied contributions from Original Research to Review Articles, Frontiers Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author by contacting the Frontiers Editorial Office: researchtopics@frontiersin.org INTERACTION BETWEEN HYALURONIC ACID AND ITS RECEPTORS (CD44, RHAMM) REGULATES THE ACTIVITY OF INFLAMMATION AND CANCER Topic Editor: David Naor, Hebrew University of Jerusalem, Israel The biological outcome of Hyaluronan (also hyaluronic acid, abbreviated HA) interaction with its CD44 or RHAMM receptors recently attracted much attention within the scientific community owing to a Nature article by Tian X et al. (Nature 2013; 499:346-9). The article described a life span exceeding 30 years in naked mole rats, whereas the maximal lifespan of mice, to which the naked mole rat is related, is only 4 years. This observation is accompanied by the finding that the naked mole rat, in contrast to the mouse, does not develop spontaneous tumors during this exceptional longevity. The article provides evidence that interaction of long tissue HA (6000-12,000 kDa) of the naked mole rat with cell surface CD44, in contrast to the interaction of short tissue HA (less than 3000 kDa) with the mouse CD44, makes the difference. More specifically, this communication shows that the interaction of short HA with fibroblasts’ CD44 imposes on them susceptibility for malignant transformation, whereas the corresponding interaction with long HA imposes on the fibroblasts a resistance to malignant transformation. The article does not explain the mechanism that underlines these findings. However, the articles, that will be published in the proposed Research Topic in the Inflammation section of Frontiers in Immunology, can bridge not only this gap, but also may explain why interaction between short HA and cell surface CD44 (or RHAMM, an additional HA receptor) enhances the development of inflammatory and malignant diseases. Furthermore, the articles included in the proposed Frontiers Research Topic will show that cancer cells and inflammatory cells share several properties related to the interaction between short HA and cell surface CD44 and/ or RHAMM. These shared properties include: 1. Support of cell migration, which allows tumor metastasis and accumulation of inflammatory cells at the inflammation site; 2. Delivery of intracellular signaling, which leads to cell survival of either cancer cells or inflammatory cells; 3. Delivery of intracellular signaling, which activates cell replication and population expansion of either cancer cells or inflammatory cells; and 4. Binding of growth factors to cell surface CD44 2 Frontiers in Immunology July 2016 | Interaction Between Hyaluronic Acid and Its Receptors of cancer cells or inflammatory cells (i.e., the growth factors) and their presentation to cells with cognate receptors (endothelial cells, fibroblasts), leading to pro-malignant or pro-inflammatory activities. Going back to the naked mole rat story, we may conclude from the proposed articles of this Frontiers Research Topic that the long HA, which displays anti- malignant effect, interferes with the above described pro-malignant potential of the short HA (perhaps by competing on the same CD44 receptor). Extrapolating this concept to Inflammation, the same mechanism (competition?) may be valid for inflammatory (and autoimmune) activities. If this is the case, long HA may be used for therapy of both malignant and inflammatory diseases. Moreover, targeting the interaction between short HA and CD44 (e.g. by anti-CD44 blocking antibodies) may display also a therapeutic effect on both malignant and inflammatory diseases, an issue that encourages not only fruitful exchange of views, but also practical experimental collaboration. Citation: Naor, D., ed. (2016). Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer. Lausanne: Frontiers Media. doi: 10.3389/978-2-88919-913-6 3 Frontiers in Immunology July 2016 | Interaction Between Hyaluronic Acid and Its Receptors Hyaluronic acid localization on pancreatic β cells. Section from pancreatic islets derived from diabetic NOD mice were subjected to double fluorescence staining with anti-insulin (green) and biotinylated hyaluronic acid binding protein (HABP ;red). DAPI staining was used to detect cell nuclei. Analysis by confocal microscopy revealed that hyaluronic acid (HA;red) are localized on β cell membrane (green). It was suggested by Nathalie Assayag-Asherie from Naor’s laboratory that the Interaction of the cell bound HA with the β cell surface CD44 imposes apoptosis on these cells resulting in type 1 diabetes (Nathalie Assayag-Asherie et.al., Can CD44 be a mediator of cell destruction ? the challenge of type 1 diabetes. PLoS One. 2015; 10(12): e0143589) 06 Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer David Naor Hyaluronan: the principal player 10 Hyaluronan synthase 1: a mysterious enzyme with unexpected functions Hanna Siiskonen, Sanna Oikari, Sanna Pasonen-Seppänen and Kirsi Rilla 21 The content and size of hyaluronan in biological fluids and tissues Mary K. Cowman, Hong-Gee Lee, Kathryn L. Schwertfeger, James B. McCarthy and Eva A. Turley 29 Revealing the mechanisms of protein disorder and N-glycosylation in CD44-hyaluronan binding using molecular simulation Olgun Guvench 38 Hyaluronan – a functional and structural sweet spot in the tissue microenvironment James Monslow, Priya Govindaraju and Ellen Puré 57 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer Nadine Nagy, Hedwich F. Kuipers, Adam R. Frymoyer, Heather D. Ishak, Jennifer B. Bollyky, Thomas N. Wight and Paul L. Bollyky 68 Lipid raft-mediated regulation of hyaluronan–CD44 interactions in inflammation and cancer Toshiyuki Murai 77 Cancer microenvironment and inflammation: role of hyaluronan Dragana Nikitovic, Maria Tzardi, Aikaterini Berdiaki, Aristidis Tsatsakis and George N. Tzanakakis 84 Hyaluronan, inflammation, and breast cancer progression Kathryn L. Schwertfeger, Mary K. Cowman, Patrick G. Telmer, Eva A. Turley and James B. McCarthy Hyaluronan interaction with its receptors – CD44 and RHAMM 96 The role of CD44 in the pathophysiology of chronic lymphocytic leukemia Julia Christine Gutjahr, Richard Greil and Tanja Nicole Hartmann 103 The where, when, how, and why of hyaluronan binding by immune cells Sally S. M. Lee-Sayer, Yifei Dong, Arif A. Arif, Mia Olsson, Kelly L. Brown and Pauline Johnson Table of Contents 4 Frontiers in Immunology July 2016 | Interaction Between Hyaluronic Acid and Its Receptors 115 The hyaluronic acid–HDAC3–miRNA network in allergic inflammation Youngmi Kim, Sangkyung Eom, Deokbum Park, Hyuna Kim and Dooil Jeoung 120 Interactions between CD44 and hyaluronan in leukocyte trafficking Braedon McDonald and Paul Kubes The pathology of hyaluronan interaction with its receptors and therapeutic strategies related to this interaction 126 Selective hyaluronan–CD44 signaling promotes miRNA-21 expression and interacts with vitamin D function during cutaneous squamous cell carcinomas progression following UV irradiation Lilly Y. W. Bourguignon and Daniel Bikle 139 Interactions between hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer Suniti Misra, Vincent C. Hascall, Roger R. Markwald and Shibnath Ghatak 170 Modulation of CD44 activity by A6-peptide Malcolm Finlayson 178 The role of CD44 in disease pathophysiology and targeted treatment Andre R. Jordan, Ronny R. Racine, Martin J. P. Hennig and Vinata B. Lokeshwar 192 CD44, hyaluronan, the hematopoietic stem cell, and leukemia-initiating cells Margot Zöller 215 CD44 acts as a signaling platform controlling tumor progression and metastasis Véronique Orian-Rousseau 5 Frontiers in Immunology July 2016 | Interaction Between Hyaluronic Acid and Its Receptors February 2016 | Volume 7 | Article 39 6 Editorial published: 08 February 2016 doi: 10.3389/fimmu.2016.00039 Frontiers in Immunology | www.frontiersin.org Edited and reviewed by: Pietro Ghezzi, Brighton and Sussex Medical School, UK *Correspondence: David Naor davidn@ekmd.huji.ac.il Specialty section: This article was submitted to Inflammation, a section of the journal Frontiers in Immunology Received: 10 January 2016 Accepted: 25 January 2016 Published: 08 February 2016 Citation: Naor D (2016) Editorial: Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer. Front. Immunol. 7:39. doi: 10.3389/fimmu.2016.00039 Editorial: interaction Between Hyaluronic acid and its receptors (Cd44, rHaMM) regulates the activity of inflammation and Cancer David Naor* Lautenberg Center of Immunology, IMRIC, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel Keywords: Cd44, rHaMM, hyaluronan, inflammation, cancer The Editorial on the Research Topic Interaction Between Hyaluronic Acid and Its Receptors (CD44, RHAMM) Regulates the Activity of Inflammation and Cancer An old Indian legend tells a story about six blind men who touched an elephant. The first man who touched his leg said: “it is a pillar.” The second man who touched the tail said: “it is a rope.” The third man who touched the trunk of the elephant said: “it is a thick branch of a tree.” The fourth man who touched the ear said: “It is a big hand fan.” The fifth man who touched the belly said: “It is a huge wall.” The sixth man who touched the tusk of the elephant said: “It is a solid pipe.” Each one of them loudly insisted that his claim is the right one. Then wise old man arrived to the place of scene, listened to their arguments and said “all of you are right, but all together you identified an elephant.” Similarly, each one of the 18 chapters of this e-book tells a different, fascinating story about the “biological polygamy” of hyaluronan and its receptors. Yet, this story is focused on the author’s specific field of interest or discipline. On the other hand, when the 18 chapters are collected in one e-book, each of them fosters the others and collectively a complete scene is created. Hyaluronan or hyaluronic acid (HA), which resides in the interstitial collagenous matrices, increases viscosity and hydration and binds to a “link module motif ” of HA-binding proteoglycans (e.g., CD44) and link proteins. HA is a non-sulfated, linear glycosaminoglycan (GAG) composed of repeating disaccharides of ( β , 1–4)-glucuronic acid (GlcUA) and ( β , 1-3)-N-acetyl glucosamine (GlcNAc). In most tissues, native HA has a high molecular mass of 1000–10,000 kDa, with extended molecular lengths of 2–20 μ m. HA plays crucial roles in structuring tissue architecture, in cell motil- ity, in cell adhesion, and in proliferation processes (1, 2). Hyaluronic acid is synthesized by three HA synthase (HAS) proteins. These generate predomi- nantly high molecular weight-HA (HMW-HA) of between 200 and 2000 kDa. HA catabolism is mediated by hyaluronidases, mechanical forces, and oxidative stress (reactive oxygen and nitrogen species). The degradation generates different-sized HA polymers (or fragments), abbreviated low molecular weight-HA (LMW-HA; < 200 kDa) and HA oligomers (1) In general (exceptions do exist), LMW-HA is pro-inflammatory and pro-cancerous, whereas HMW-HA is anti-inflammatory and anti-cancerous. In this context, a vicious cycle is generated. Inflammatory conditions activate the production of HAS, which synthesizes HA. Subsequently, the HA is degraded by hyaluronidases and reactive oxygen species, the generation of which is also induced by the inflammation. The resulting cleaved HA fragments further propagate the inflamma- tion. This perpetuating cycle can be blocked by competition with excess HMW-HA. To this end, Tian et al. found that naked mole-rat fibroblasts secrete HMW-HA, which is over five times larger (6000–12000 kDa), than human or mouse HA (500–2000 kDa). The HMW-HA accumulates in naked February 2016 | Volume 7 | Article 39 7 Naor Hyaluronic Acid and Its R eceptor Frontiers in Immunology | www.frontiersin.org mole-rat tissues. This rodent has a lifespan exceeding 30 years and is resistant to cancer. Interestingly, once HMW-HA is removed by knocking down HAS-2, or by overexpressing hyaluronidase 2, which cleaves HMW-HA, the naked mole-rat cells become susceptible to malignant transformation and form tumors (3). Notably, the pro-inflammatory role of LMW-HA, including HA fragments and oligo-HA, displays not only pathological effects but eventually also physiological activities, such as expression of β -defensins to combat microbial infections (4) or induction of inflammation to accelerate wound healing (5). CD44 glycoprotein is expressed on the surface of many mam- malian cells, including leukocytes, endothelial cells, epithelial cells, fibroblasts, and keratinocytes. Extensive alternative splicing of nine variable exons and distinct post-translational modifica- tions generate many CD44 isoforms. Standard CD44 is the smallest and most abundant isoform, whereas the other variants are expressed in a cell-specific manner (e.g., on epithelial cells or keratinocytes), as well as in multiple pathologies, including rheumatoid arthritis, diabetes, multiple sclerosis, and cancer (2, 6). The physiological activities of CD44 stem from its multiple functions, including mediating cell–cell and cell–matrix interac- tions, cell proliferation, cell adhesion, cell migration, hemat- opoiesis, lymphocyte activation, cell homing, cell extravasation, cell survival, and apoptosis, as well as epithelial–mesenchymal transition (EMT) (7). However, these functions can be converted to pathological activities when exaggerated or they escape out of control, like in cancer or chronic inflammation. Most of the CD44 studies are limited to preclinical models. However, the use of anti-CD44 antibodies in a few clinical trials resulted in life-threatening toxicity (8). Therefore, the risks vs. the benefits must be carefully evaluated before CD44-targeting strategies are translated to the clinic. The receptor for HA-mediated motility (RHAMM or CD168), such as CD44, is also alternatively spliced, albeit at a much lower intensity. Variant forms of RHAMM are found on both cell surfaces and inside the cells (9). However, unlike CD44, RHAMM isoforms do not have the link module domain. Instead, they have a BX7B motif that binds HA, where “B” represents arginine or lysine, and “X” represents any non-acidic amino acid (10). RHAMM supports both malignancy and wound healing processes. As CD44 supports both chronic inflammation and cancer pro- gression in many (but not all) experimental models and human diseases, CD44 targeting, e.g., by antibody, was successfully docu- mented in many preclinical studies, such as collagen-induced arthritis (CIA) (11). Surprisingly, we found that CD44 targeting by CD44 gene deletion in the embryo aggravates CIA, rather than ameliorating it. It appears that a CD44 redundancy process in the CD44 deleted embryo allows up-regulation of RHAMM, which replaces CD44 also during adulthood. The substituting RHAMM supports CIA joint inflammation more effectively than CD44 (11), because it is a better supporter of cell migration. It is not surprising that CD44 targeting in the adult is not redundant, like in the embryo, as CD44 in the embryo displays a survival-sup- porting function that generates pressure for ultimate RHAMM replacement. Such a developmental pressure does not exist in the adult, so that CD44 targeting is not compensated by functional RHAMM at this phase of life, and the therapeutic effect by CD44 targeting, can be documented. TLR-4, a principle innate receptor of bacterial LPS, is also an important receptor of HA (1). TLR-4 activates nuclear factor (NF)- κ B protein via two major routes: a myeloid differentiation factor (MyD) 88-dependent pathway that acts via NF- κ B to induce pro-inflammatory cytokines and a MyD88-independent pathway that acts via type I interferons to increase the expression of interferon-inducible pro-inflammatory genes. Siiskonen et al. describe the mysterious and unexpected functions of hyaluronan synthase 1 (HAS-1), which is less known and less explored than its two HAS-2 and HAS-3 enzyme “step brothers,” which also engage in HA synthesis. As HAS-1 embryonic gene deletion does not influence the normal pheno- type, this raises the questions: are its functions compensated (by redundancy) by the two other HAS enzymes, and if so, why has HAS-1 has been preserved in the course of evolution? Receptor (e.g., CD44) sensitivity to hyaluronan quantity and size provides a biosensor of the state of the microenvironment (inflammation, cancer stroma, or wound healing) surrounding the cell. Hence, to learn more on the chemical profile of HA in the context of these parameters or on technologies associated with its quantification, specification, isolation, and size determination in both fluids and tissues, it would be highly beneficial to read Cowman et al. communication. Readers interested in the structural alternations associated with the HA-binding domain (HABD) of CD44 after HA binding, cannot miss Guvench’s chapter. The authors (Guvench et al.) per- formed extensive all-atom explicit-solvent molecular dynamics (MD) simulations of HABD and the conclusions are presented in this communication. However, the HABD was analyzed indepen- dently of the rest of the CD44 molecule, while the transmembrane domain and especially the cytoplasmic tail influence the binding affinity as well (2, 6). Furthermore, it should be recalled that in this study, the conclusions are limited to HABD interaction with HA oligomers, whereas larger HA molecules were not evaluated. Monslow et al. comprehensively reviewed the role of HA in health and disease, especially in relation to HA size. Their size definition for HA is formulated as follows: HMW-HA: > 1000 kDa; intermediate (medium) molecular weight-HA (MMW-HA): 250–1000 kDa; LMW-HA: > 10–250 kDa; and oligo-HA ( < 10 kDa). However, there is no consensus on these definitions and standardization of these values by an interna- tional workshop is necessary. In general, there is a consensus that HMW-HA controls normal homeostasis and displays anti-inflammatory and anti-cancerous effects, with a few excep- tions. Many researchers consider LMW-HA and oligo-HA pro- inflammatory and pro-cancerous GAGs, as well as stimulators of pro-inflammatory cytokines. Yet, there are many contradictory findings. This confusion is related to the lack of consensus on size definition, polydispersity of HA commercial products (differ- ent HA sizes in the same product), the use of HA from different animal sources or from different tissues, and, finally, the impurity of commercial products. These reservations must be taken into account whenever a new study on HA is undertaken. February 2016 | Volume 7 | Article 39 8 Naor Hyaluronic Acid and Its R eceptor Frontiers in Immunology | www.frontiersin.org Four-methylumbelliferone (4-MU) is an HA-antagonizing product, described by Nagy et al. The product inhibits HAS synthesis by reducing the availability of UDP-GlcUA to the enzyme, thus, interfering with HA synthesis and consequently with HA-related pathologies, such as cancer and autoimmunity. As 4-MU is an already approved drug called “hymecromone” for biliary spasm, the road to 4-MU therapy of inflammatory diseases and malignancy has been largely paved. Hyaluronan and CD44 reside in the lipid rafts, cholesterol- and glycosphingolipid-enriched membrane microdomains that regulate the membrane receptors as well as signal delivery from the cell surface into the cell. Murai et al. examines in particular lipid raft regulation of HA binding to the CD44 of T lymphocytes and malignant cells, binding, which leads to rolling interactions on vascular endothelial cells, an important phase in inflammation and cancer development. If the reader centers his/her interest on the inter-relationship between the tumor and its inflammatory microenvironment in context to HA, he/she can be referred to the article by Nikitovic et al. The authors focus their discussion on the influence of the cancer inflammatory environment on tumor growth, with spe- cific emphasis on stromal HA. The interplay between the tumor and its stromal microenvi- ronment is also documented by Schwertfeger et al., using breast cancer as an example. The generation of a pro-tumorigenic inflammatory environment during breast cancer development requires LMW-HA-induced recruitment and activation of inflam- matory macrophages. The macrophages release NFkB-regulated pro-inflammatory factors (IL-1 β , IL-12, reactive oxygen species), normally involved in tissue repair. Hence, the cancer cells “stole” the inflammation supportive machinery from the wound healing process. Such inter-relationships between the tumor and its micro- environment are described also in hematological tumors. Gutjahr et al. call our attention to the pro-cancerous survival (or anti-apoptotic) signals delivered by the tumor inflammatory environment, focusing on acute lymphocytic leukemia (CLL). Long-term survival and proliferation of CLL cells requires their dynamic interaction with stromal and immune cells in lymphoid organs. Interactions of HA with cell surface CD44 or RHAMM contribute to CLL cell localization, and hence to CLL pathophysiology. Deep mining of these complex interactions may reveal links more susceptible to therapeutic targeting, such as CD44v6, RHAMM, VLA-4, ZAP-70, or HAS (for details, see this communication). Lee-Sayer et al. focus their attention on the inter-relationships between HA and CD44 in cells involved in the innate and adop- tive immune system in the context of inflammation. Under innate inflammatory conditions, dendritic cells express HA on their membrane and T cells upregulate CD44. In the adoptive phase, interactions between the HA of the antigen-presenting dendritic cells and the activated CD44 of T lymphocytes may allow intimate contact between the co-stimulating molecules of the former and accessory molecules of the latter, leading to activation of the lymphocyte’s T cell receptor. Going one step further, the HA and the CD44 molecules may also be considered co-stimulating and accessory molecules. If the reader wants to know how HMW-HA and LMW-HA are involved in allergic inflammation, he/she should focus on the communication by Kim et al. The reader can surmise, following extrapolation from the inflammation data, that HMW-HA is anti-allergic, whereas LMW-HA is pro-allergic. The mechanisms underlying these effects, including the role of microRNAs, are reported in detail. McDonald and Kubes describe the cell trafficking roles on endothelial cells in the liver, which are different than those in other tissues. Recent evidence implicates serum-derived hyalu- ronan-associated protein (SHAP) as an important co-factor that strengthens the binding of HA to CD44 under shear stress, result- ing in improved cell extravasation. Finally, the authors indicate that HA–CD44 interaction supports not only destructive chronic inflammation but also the trafficking of stem cells that resolve the inflammation, the balance between the two determining the tissue’s fate. Bourguignon and Bikle suggest that the interaction of large HA ( > 1000 kDa) with cell surface CD44 leads to Rac-signaling and normal keratinocyte differentiation, DNA repair, and survival function. On the other hand, the interaction of small/fragmented (10–100 kDa) HA (generated by UV irradiation) with cell surface CD44 stimulates RhoA/ROC activation, NF κ B/Stat-3 signaling, and microRNA-21 production, resulting in proliferation and inflammation, as well as in the progression of squamous cell car- cinomas (SCC). A balance that favors the “good” Rac-signaling over the “bad” RhoA signaling can be generated by Y27623, a ROK inhibitor, vitamin D, or by triggering HAS-2, which acti- vates the production of large HA. These therapeutic approaches may be used for therapy of patients with UV irradiation-skin diseases (for more details, see the article). Misra et al. comprehensively describe technologies that can be used to modulate the signals of HA–HA receptor interactions in favor of the patient. A sophisticated approach is Misra’s technol- ogy relating to transferrin-coated nanoparticles, which include CD44v6 shRNA, to silence the CD44v6 gene in tumor cells expressing transferrin receptor. Readers, who seek information on this fascinating approach, or to other therapeutic strategies based on disrupting HA–CD44 interactions and subsequent signaling, are invited to read this chapter. The use of a CD44-targeting peptide, Ac-KPSSPPEE-NH2, is another therapeutic strategy, documented by Finlayson, to combat CD44-associated pathological activities in experimental vascularized eye, tumor xenografts, or in clinical trials. If the reader wishes to know more on the peptide’s mechanism of action, it is recommended to read this chapter. Jordan et al. focuses our attention on normal and aberrant cel- lular signaling generated after interaction of HA with its receptor (mainly CD44), under different physiological and pathological settings. These include bacterial infection, viral infection, inter- stitial lung disease, wound healing, chronic inflammation (auto- immunity), and cancer. The outcome of such aberrant signaling is uncontrolled cell migration, cell proliferation, cell survival (e.g., of cancer cells), apoptosis [e.g., of β cells in type 1 diabetes; (12)], angiogenesis, and EMT, leading to different pathologies. Both hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs), also known as leukemia-initiating cells (LICs) seek February 2016 | Volume 7 | Article 39 9 Naor Hyaluronic Acid and Its R eceptor Frontiers in Immunology | www.frontiersin.org a “shelter” called a bone marrow “niche.” The niche maintains the “ stemness” of the host cells, i.e., supports their survival and hom- ing as well as regulates the balance between their quiescence and growth. Once HSCs are transplanted into a leukemic patients, they eventually compete with LICs for lodging in the niche, engaging their cell surface CD44 in interaction with the HA of the niche. In this communication, Zöller raises the question: how can an advantage be imparted to the transplanted HSCs over the patient’s LICs in the context of HA–CD44 interaction, in view of their largely identical biological nature, when they compete for “shelter” in the same niche. The answer to the question may be found in this communication. Orian-Rousseau’s communication is focused on the role of CD44 isoforms as co-receptors, especially for receptor tyrosine kinases (RTK). She further calls our attention to the involve- ment of CD44 in Wnt signaling, both as a regulator of the Wnt receptor (via interaction with LRP6) or as a Wnt target gene, e.g., for CD44v6 or Met-RTK expression. Involvement of CD44 in Wnt signaling, leading to EMT, is also discussed. Finally, Dr Orian-Rousseau speculates on the function of CD44 in cancer stem cells (CSCs), which has so far has been studied as a biomarker for these cells, but its role in CSCs remains elusive. Integration of the CD44v6 co-receptor (activated by HA ?) and Met-RTK (activated by hepatocyte growth factor) with Wnt signaling may explain what could be the role of CSC CD44 in colorectal cancer and perhaps other malignancies, i.e., by promotion of cell migra- tion and metastasis. In conclusion, the elephant unveiled in this e-book reveals a fascinating story about the HA–CD44 interaction, which not only exposes the underlying mechanism of this interaction but also allows identification of weak links, which can be targeted by various therapeutic approaches in both cancer and inflammatory diseases. aUtHor CoNtriBUtioNS The author confirms being the sole contributor of this work and approved it for publication. rEFErENCES 1. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 91 (1):221–64. doi:10.1152/physrev.00052.2009 2. Naor D, Sionov RV, Ish-Shalom D. CD44: structure, function, and association with the malignant process. Adv Cancer Res (1997) 71 :241–319. doi:10.1016/ S0065-230X(08)60101-3 3. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature (2013) 499 (7458):346–9. doi:10.1038/nature12234 4. Hill DR, Kessler SP, Rho HK, Cowman MK, delaMotte CA. Specific-sized hyaluronan fragments promote expression of human β -defensin 2 in intestinal epithelium. J Biol Chem (2012) 287 :30610–24. doi:10.1074/jbc.M112.356238 5. Tolg C, Telmer P, Turley E. Specific sizes of hyaluronan oligosaccharides stim- ulate fibroblast migrationan and excisional wound repair. PLoS One (2014) 9 (2):e88479. doi:10.1371/journal.pone.0088479 6. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y. CD44 in cancer. Crit Rev Clin Lab Sci (2002) 39 (6):527–79. doi:10.1080/10408360290795574 7. Xu H, Tian Y, Yuan X, Wu H, Liu Q, Pestell RG, et al. The role of CD44 in epithelial-mesenchymal transition and cancer development. Onco Targets Ther (2015) 16 (8):3783–92. doi:10.2147/OTT.S95470 8. Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esopha- gus. Clin Cancer Res (2006) 12 (20 Pt 1):6064–72. doi:10.1158/1078-0432. CCR-06-0910 9. Zhang S, Chang MC, Zylka D, Turley S, Harrison R, Turley EA. The hyaluro- nan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem (1998) 273 :11342–8. doi:10.1074/jbc.273.18.11342 10. Yang B, Yang BL, Savani RC, Turley EA. Identification of a common hyaluro- nan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J (1994) 13 :286–96. 11. Nedvetzki S, Gonen E, Assayag N, Reich R, Williams RO, Thurmond RL, et al. RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci U S A (2004) 101 (52):18081–6. doi:10.1073/ pnas.0407378102 12. Assayag-Asherie N, Sever D, Bogdani M, Johnson P, Weiss T, Ginzberg A, et al. Can CD44 be a mediator of cell destruction? The challenge of type 1 diabetes. PLoS One (2015) 10 (12):e0143589. doi:10.1371/journal. pone.0143589 Conflict of Interest Statement: The author declares that the research was con- ducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2016 Naor. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. REVIEW ARTICLE published: 05 February 2015 doi: 10.3389/fimmu.2015.00043 Hyaluronan synthase 1: a mysterious enzyme with unexpected functions Hanna Siiskonen 1 , Sanna Oikari 2 , Sanna Pasonen-Seppänen 2 and Kirsi Rilla 2 * 1 Department of Dermatology, Kuopio University Hospital, University of Eastern Finland, Kuopio, Finland 2 Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland Edited by: David Naor, Hebrew University of Jerusalem, Israel Reviewed by: Alberto Passi, Università degli Studi dell’Insubria, Italy Timothy Bowen, Cardiff University, UK *Correspondence: Kirsi Rilla, Institute of Biomedicine, University of Eastern Finland, Yliopistonranta 1 E, Kuopio 70211, Finland e-mail: kirsi.rilla@uef.fi Hyaluronan synthase 1 (HAS1) is one of three isoenzymes responsible for cellular hyaluro- nan synthesis. Interest in HAS1 has been limited because its role in hyaluronan production seems to be insignificant compared to the two other isoenzymes, HAS2 and HAS3, which have higher enzymatic activity. Furthermore, in most cell types studied so far, the expres- sion of its gene is low and the enzyme requires high concentrations of sugar precursors for hyaluronan synthesis, even when overexpressed in cell cultures. Both expression and activity of HAS1 are induced by pro-inflammatory factors like interleukins and cytokines, suggesting its involvement in inflammatory conditions. Has1 is upregulated in states asso- ciated with inflammation, like atherosclerosis, osteoarthritis, and infectious lung disease. In addition, both full length and splice variants of HAS1 are expressed in malignancies like bladder and prostate cancers, multiple myeloma, and malignant mesothelioma. Interest- ingly, immunostainings of tissue sections have demonstrated the role of HAS1 as a poor predictor in breast cancer, and is correlated with high relapse rate and short overall survival. Utilization of fluorescently tagged proteins has revealed the intracellular distribution pattern of HAS1, distinct from other isoenzymes. In all cell types studied so far, a high proportion of HAS1 is accumulated intracellularly, with a faint signal detected on the plasma membrane and its protrusions. Furthermore, the pericellular hyaluronan coat produced by HAS1 is usually thin without induction by inflammatory agents or glycemic stress and depends on CD44–HA interactions. These specific interactions regulate the organization of hyaluronan into a leukocyte recruiting matrix during inflammatory responses. Despite the apparently minor enzymatic activity of HAS1 under normal conditions, it may be an important factor under conditions associated with glycemic stress like metabolic syndrome, inflammation, and cancer. Keywords: hyaluronan, hyaluronan synthase, CD44, inflammation, cytokines, cancer INTRODUCTION Hyaluronan is the most abundant matrix polysaccharide, which maintains tissue homeostasis, gives compressive strength for tis- sues, acts as an ideal lubricant in body fluids and accelerates growth and healing. In addition, excess hyaluronan promotes cancer progression and mediates inflammation. Therefore, membrane- bound hyaluronan synthases (HAS1–3), special enzymes respon- sible for hyaluronan production, have a key role in regulation of these conditions. Despite highly homologous amino acid sequences, HAS’s differ in subcellular localization, enzymatic activity, and regulation (1). Despite almost 20 years of active research to sequence hyaluro- nan synthase genes, it is not known why vertebrates have three different isoforms of these enzymes, which are coded by separate genes on different chromosomes, to synthesize a single sugar poly- mer. Most research has focused on HAS2 and HAS3, while HAS1 has received the least attention and remains the most enigmatic, with only a few published reports of its biological effects on cellular behavior or association with disease states. Knocking out the activity of hyaluronan synthase genes has provided a better understanding about normal HAS function. Knockout of Has2 results in embryonic lethality with severe car- diac and vascular malformations (2), while the knockout of Has1 or Has3 does not have any apparent phenotype under non-stressed conditions (3, 4). However, double knockout of Has1 and Has3 leads to enhanced inflammation and accelerated wound closure of mouse skin (5), suggesting tha